The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•6 April 2026•

1 min read

Thermo Fisher Launches Gibco CTS Compleo System for Cell Therapy Manufacturing

Key Facts

1Thermo Fisher Scientific launched the Gibco CTS Compleo system, an automated and functionally closed system to enhance cell therapy manufacturing.

2The system aims to reduce manual intervention and improve consistency in formulation and filling processes.

3The system is part of the Gibco Cell Therapy Systems portfolio to support GMP-compliant manufacturing.

Create Free Account

Thermo Fisher Scientific (TMO) has officially launched the Gibco CTS Compleo system, a functionally closed and automated solution designed to streamline cell therapy manufacturing. The new system specifically targets the formulation and filling stages, which are often critical bottlenecks in the production process. By reducing manual intervention, the platform aims to enhance consistency and minimize the risk of errors in complex biotech workflows. As part of the broader Gibco Cell Therapy Systems portfolio, the system is fully compliant with Good Manufacturing Practice (GMP) standards. This launch reinforces Thermo Fisher's leadership in the high-growth life sciences sector by providing scalable solutions for advanced therapies. Analysts view this move as a strategic step to capture more market share in the expanding cell therapy services market.